





Product Catalog		
Product	Specification	Picture
FlashAngio™ caFFR™ System	ASC15	
FlashPressure™ Transducer	CPT-1200	
	CPT-1500	
	CPT-2000	



**For further information and contact us**

For more information and a demonstration, please send email to [InternationalBD@rainmed.com](mailto:InternationalBD@rainmed.com) or visit [www.rainmed.com](http://www.rainmed.com).

**Reference list**

1. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. FAME study. N Engl J Med. 2009;360(3):213-24.
2. Angiographic Versus Functional Severity of Coronary Artery Stenoses in the FAME Study : Fractional Flow Reserve Versus Angiography in Multivessel Evaluation. Journal of the American College of Cardiology, 2010, 55(25):2816-21
3. Fearon WF. FAME 2 Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR-Guided PCI in Patients with Stable Coronary Artery Disease Presented at Late Breaking Clinical Trials 1 at TCT 2012, Miami, Florida, October 24, 2012.
4. De Bruyne B, Pijls N, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991-1001.
5. 2018 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal (2019) 40, 87–165
6. Kushner FG, hand M, smith sC Jr, et al. 2009 focused updates: aCC/aha guidelines for the management of patients with st-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and aCC/aha/sCal guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update)
7. Jelmer Westra,Diagnostic Accuracy of On-line Quantitative Flow Ratio Functional Assessment by Virtual Online Reconstruction: FAVOR 2 Europe-Japan,2017.
8. Jianping Li, Huo Yong, Ziad Ali et.al. Accuracy of computational pressure-fluid dynamics applied to coronary angiography to derive fractional flow reserve: FLASH FFR European Society of Cardiology:Cardiovasc Res. 2019 Nov 5. pii: cvz289. doi: 10.1093/cvr/cvz289

Please check with your RainMed Medical representative for product availability in your country.  
Please review the Instructions for Use prior to using these devices for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.  
caFFR , FlashAngio and FlashPressure are designed, developed and manufactured by RainMed Medical Technology Inc. caFFR, FlashAngio and FlashPressure are registered and unregistered trademarks and service marks of RainMed Medical Technology Inc. and its related companies. ©2019 Suzhou RainMed Medical Technology Co. Ltd. All rights reserved.

INTRODUCING

# FlashAngio™

# caFFR™

Novel Platform for Coronary Physiologic Guidance

caFFR™

New approach getting precision FFR



Empowering Guidance

- Used for more applications easier than ever
- Adjusted based on Medina bifurcation classification
- Simplified Multivessels interrogation



Superior Accuracy

Accuracy Comparison	Rainmed CAFFR	Cathworks FFRangio	Medis QFR
	95.7% <sup>8</sup>	92%	86% <sup>7</sup>

89.9% accuracy when FFR between 0.75 - 0.85



Integrated Workflow

- Non Invasive, No adenosine
- Liberate Cardiologists to more comprehensive vision with Physicians/Assitants help



Free Up Your Time






- Dedicated designed CFD algorithm offers accurate resolution to Navier–Stokes formula in 10 seconds






# caFFR™

## A Milestone of FFR Measurement



Multiple Lesions




Bifurcation Lesion

# Physiology-guide Revascularization Decision Making

## FAME & FAME II

- Allows more accurate identification of hemodynamically relevant stenosis.<sup>1</sup>
- Reduces mortality and myocardial infarction by 34% at two years.<sup>2</sup>
- The MACE happened to FFR-guided PCI group were significantly lower than the medical therapy group.<sup>3-4</sup>
- 86% relative reduction in the risk for ACS requiring unplanned hospital readmission with urgent revascularization.
- Cost-effectiveness-ICER of \$32,000 per QALY.



## Study Result

- Patients with moderate stenosis (50-70% Stenosis) . 1/3 of them will be ignored if by angiography alone.
- Patients with severe stenosis (>70% Stenosis). 20% of them might be over-treated if decided by angiography alone.

## Supported By Guidelines

- FFR is awarded the highest level of evidence, Class I, level of Evidence a, by the European society of Cardiology (ESC) and the European association for Cardio-thoracic surgery (EACTS).<sup>5</sup>
- The ACC/AHA/SCAI guidelines are Class II a, level of Evidence a, for determining whether PCI of a specific coronary lesion is warranted.<sup>6</sup>

## Accuracy of computational pressure-fluid dynamics applied to coronary angiography to derive fractional flow reserve: FLASH FFR

Jianping Li<sup>1†</sup>, Yanjun Gong<sup>1†</sup>, Weimin Wang<sup>2</sup>, Qing Yang<sup>3</sup>, Bin Liu<sup>4</sup>, Yuan Lu<sup>5</sup>, Yawei Xu<sup>6</sup>, Yunlong Huo<sup>7\*</sup>, Tiesi Yi<sup>1</sup>, Jian Liu<sup>2</sup>, Yongle Li<sup>3</sup>, Shaopeng Xu<sup>3</sup>, Lei Zhao<sup>4</sup>, Ziad A. Ali<sup>8,9,10</sup>, and Yong Huo<sup>1\*</sup>

<sup>1</sup>Department of Cardiology, Peking University First Hospital, Beijing, China; <sup>2</sup>Department of Cardiology, Peking University People's Hospital, Beijing, China; <sup>3</sup>Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China; <sup>4</sup>Department of Cardiology, The Second Hospital of Jilin University, Changchun, Jilin, China; <sup>5</sup>Department of Cardiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; <sup>6</sup>Department of Cardiology, Shanghai Tenth People's Hospital, Shanghai, China; <sup>7</sup>PKU-HKUST Shenzhen-Hongkong Institution, Shenzhen, China; <sup>8</sup>Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA; <sup>9</sup>Department of Medicine, NewYork-Presbyterian Hospital Columbia University Medical Center, New York, NY, USA; and <sup>10</sup>St. Francis Hospital, Roslyn, NY, USA

Received 28 June 2019; revised 12 September 2019; editorial decision 19 October 2019; accepted 3 November 2019

## Diagnostic Characteristics of caFFR

All Interrogated Vessel No.	328
Diagnostic accuracy	95.7 %
Sensitivity	90.4 %
Specificity	98.6 %
Positive Predictive Value	97.2 %
Negative Predictive Value	95.0 %

## Relevance and Consistency of CAFFR and FFR

